8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 19, 2026·SEC
Material company update
Nov 3, 2025·SEC
Pediatrix Medical Group, Inc.(MD)Earnings, Financials & Key Ratios
MD•NYSE
$22.21
$1.85B mkt cap·11.4× P/E·Price updated May 6, 2026
AboutPediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.Show more
- Revenue$1.91B-4.9%
- EBITDA$253M+793.2%
- Net Income$165M+266.9%
- EPS (Diluted)1.94+263.0%
- Gross Margin24.66%+9.2%
- EBITDA Margin13.21%+829.1%
- Operating Margin12.07%+453.7%
- Net Margin8.64%+275.6%
- ROE20.28%+265.2%
- ROIC14.76%+483.1%
- Debt/Equity0.76-11.9%
- Interest Coverage7.02+571.8%
MD Key Insights
Pediatrix Medical Group, Inc. (MD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak 3Y average ROE of 0.4%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MD Price & Volume
Pediatrix Medical Group, Inc. (MD) stock price & volume — 10-year historical chart
Loading chart...
MD Growth Metrics
Pediatrix Medical Group, Inc. (MD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-3.66%
5 Years1.99%
3 Years-0.99%
TTM-2.25%
Profit CAGR
10 Years-6.85%
5 Years-
3 Years35.6%
TTM311.52%
EPS CAGR
10 Years-5.94%
5 Years-
3 Years34.91%
TTM300.98%
Return on Capital
10 Years6.25%
5 Years5.14%
3 Years3.23%
Last Year13.18%
MD Recent Earnings
Pediatrix Medical Group, Inc. (MD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$0.44
Est $0.37
+18.9%
Revenue
$476M
Est $466M
+2.2%
Q1 2026
Feb 19, 2026EPS
$0.50
Est $0.53
-5.7%
Revenue
$494M
Est $486M
+1.6%
Q4 2025
Nov 3, 2025EPS
$0.67
Est $0.46
+45.7%
Revenue
$493M
Est $486M
+1.4%
Q3 2025
Aug 5, 2025EPS
$0.53
Est $0.42
+26.2%
Revenue
$469M
Est $474M
-1.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.44vs $0.37+18.9% | $476Mvs $466M+2.2% |
| Q1 2026 | Feb 19, 2026 | $0.50vs $0.53-5.7% | $494Mvs $486M+1.6% |
| Q4 2025 | Nov 3, 2025 | $0.67vs $0.46+45.7% | $493Mvs $486M+1.4% |
| Q3 2025 | Aug 5, 2025 | $0.53vs $0.42+26.2% | $469Mvs $474M-1.0% |
Based on last 12 quarters of dataView full earnings history →
MD Peer Comparison
Pediatrix Medical Group, Inc. (MD) competitors in Physician platforms and value-based care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 THC | 17.04B | 194.51 | 12.56 | 3.12% | 7.94% | 19.56% | 1.47 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 AMSF | 556.33M | 29.60 | 11.98 | 2.63% | 14.27% | 9.68% | 0.00 | |
 HCA | 96.01B | 429.45 | 15.13 | 7.08% | 8.97% | |||
 UHS | 10.55B | 168.49 | 7.29 | 9.71% | 8.56% | 20.65% | 0.74 | |
 CYH | 404.47M | 2.87 | 0.76 | -1.18% | -0.41% | |||
 ACHC | 2.33B | 25.30 | -2.08 | 5.04% | -32.84% | -40.92% | 1.24 | |
 SEM | 2.04B | 16.43 | 13.92 | 5.12% | 2.42% | 6.57% | 1.82 |
Compare MD vs Peers
Pediatrix Medical Group, Inc. (MD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MD Income Statement
Pediatrix Medical Group, Inc. (MD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.46B | 3.65B | 1.78B | 1.73B | 1.91B | 1.97B | 1.99B | 2.01B | 1.91B | 1.93B |
| Revenue Growth % | 8.64% | 5.46% | -51.2% | -2.57% | 10.22% | 3.18% | 1.15% | 0.92% | -4.92% | -2.25% |
| Cost of Goods Sold | 2.46B | 2.66B | 1.28B | 1.28B | 1.4B | 1.5B | 1.57B | 1.56B | 1.44B | 1.07B |
| COGS % of Revenue | 71.08% | 72.87% | 71.73% | 74.09% | 73.15% | 76.32% | 78.87% | 77.43% | 75.34% | - |
| Gross Profit | 1B▲ 0% | 989.51M▼ 1.1% | 503.09M▼ 49.2% | 449.32M▼ 10.7% | 513.24M▲ 14.2% | 467.03M▼ 9.0% | 421.56M▼ 9.7% | 454.34M▲ 7.8% | 471.88M▲ 3.9% | 385.43M▲ 0% |
| Gross Margin % | 28.92% | 27.13% | 28.27% | 25.91% | 26.85% | 23.68% | 21.13% | 22.57% | 24.66% | 19.95% |
| Gross Profit Growth % | -3.24% | -1.06% | -49.16% | -10.69% | 14.23% | -9% | -9.74% | 7.78% | 3.86% | - |
| Operating Expenses | 519.98M | 543.66M | 331.33M | 351.19M | 310.32M | 294.35M | 414.24M | 523.06M | 240.79M | 637.38M |
| OpEx % of Revenue | 15.04% | 14.91% | 18.62% | 20.25% | 16.24% | 14.93% | 20.77% | 25.99% | 12.58% | - |
| Selling, General & Admin | 417.11M | 432.38M | 244.51M | 248.95M | 263.36M | 231.4M | 227.54M | 238.44M | 240.79M | 242.45M |
| SG&A % of Revenue | 12.06% | 11.86% | 13.74% | 14.36% | 13.78% | 11.73% | 11.41% | 11.85% | 12.58% | - |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 102.88M | 111.28M | 86.82M | 102.24M | 46.97M | 62.95M | 186.7M | 284.62M | 0 | 3M |
| Operating Income | 480.08M▲ 0% | 445.85M▼ 7.1% | 171.76M▼ 61.5% | 98.13M▼ 42.9% | 202.92M▲ 106.8% | 172.69M▼ 14.9% | 7.32M▼ 95.8% | -68.71M▼ 1038.6% | 231.09M▲ 436.3% | 224.25M▲ 0% |
| Operating Margin % | 13.88% | 12.22% | 9.65% | 5.66% | 10.62% | 8.76% | 0.37% | -3.41% | 12.07% | 11.61% |
| Operating Income Growth % | -16.02% | -7.13% | -61.48% | -42.87% | 106.78% | -14.9% | -95.76% | -1038.57% | 436.3% | - |
| EBITDA | 582.96M | 529.68M | 197.69M | 126.57M | 235.06M | 208.32M | 43.49M | -36.49M | 252.91M | 246.86M |
| EBITDA Margin % | 16.86% | 14.52% | 11.11% | 7.3% | 12.3% | 10.56% | 2.18% | -1.81% | 13.21% | 12.78% |
| EBITDA Growth % | -11.8% | -9.14% | -62.68% | -35.97% | 85.72% | -11.38% | -79.12% | -183.89% | 793.16% | 1077.52% |
| D&A (Non-Cash Add-back) | 102.88M | 83.83M | 25.93M | 28.44M | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M | 22.61M |
| EBIT | 460.23M | 443.85M | 177.71M | 117.63M | 203.95M | 121.06M | -6.28M | -60.6M | 252.4M | 209.27M |
| Net Interest Income | -74.56M | -92.94M | -118.93M | -110.48M | -68.72M | -39.7M | -42.08M | -40.74M | -16.92M | -16.23M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.05M | 4.7M |
| Interest Expense | 74.56M | 92.94M | 118.93M | 110.48M | 68.72M | 39.7M | 42.08M | 40.74M | 35.97M | 12.66M |
| Other Income/Expense | -69.65M | 120.45M | -112.97M | -90.98M | -67.69M | -91.32M | -55.68M | -32.63M | -14.65M | 2.94M |
| Pretax Income | 410.42M▲ 0% | 368.84M▼ 10.1% | 58.78M▼ 84.1% | 7.15M▼ 87.8% | 135.23M▲ 1791.8% | 81.37M▼ 39.8% | -48.36M▼ 159.4% | -101.34M▼ 109.6% | 216.43M▲ 313.6% | 227.19M▲ 0% |
| Pretax Margin % | 11.87% | 10.11% | 3.3% | 0.41% | 7.08% | 4.13% | -2.42% | -5.03% | 11.31% | 11.76% |
| Income Tax | 90.05M | 100.21M | 16.58M | 16.73M | 27.24M | 18.81M | 12.05M | -2.27M | 51.04M | 34.42M |
| Effective Tax Rate % | 21.94% | 27.17% | 28.2% | 234.02% | 20.14% | 23.11% | -24.92% | 2.24% | 23.58% | 15.15% |
| Net Income | 320.37M▲ 0% | 268.63M▼ 16.2% | -1.5B▼ 657.5% | -796.49M▲ 46.8% | 130.96M▲ 116.4% | 66.33M▼ 49.3% | -60.41M▼ 191.1% | -99.07M▼ 64.0% | 165.39M▲ 266.9% | 174.22M▲ 0% |
| Net Margin % | 9.26% | 7.37% | -84.15% | -45.93% | 6.85% | 3.36% | -3.03% | -4.92% | 8.64% | 9.02% |
| Net Income Growth % | -1.4% | -16.15% | -657.54% | 46.82% | 116.44% | -49.35% | -191.06% | -64% | 266.94% | 311.52% |
| Net Income (Continuing) | 305.44M | 258.61M | 42.21M | -9.58M | 107.99M | 62.56M | -60.41M | -99.07M | 165.39M | 174.22M |
| Discontinued Operations | 14.93M | 147.12M | -1.54B | -786.91M | 22.95M | 3.77M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 232K | 205K | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 3.42▲ 0% | 2.93▼ 14.3% | -17.94▼ 712.3% | -9.55▲ 46.8% | 1.52▲ 115.9% | 0.79▼ 48.0% | -0.73▼ 192.4% | -1.19▼ 63.0% | 1.94▲ 263.0% | 2.10▲ 0% |
| EPS Growth % | -1.44% | -14.33% | -712.29% | 46.77% | 115.92% | -48.03% | -192.41% | -63.01% | 263.03% | 300.98% |
| EPS (Basic) | 3.42 | 2.95 | -17.78 | -9.31 | 1.52 | 0.80 | -0.72 | -1.19 | 1.94 | - |
| Diluted Shares Outstanding | 93.72M | 91.61M | 84.25M | 85.59M | 86.42M | 84.12M | 82.2M | 83.33M | 85.27M | 83.08M |
| Basic Shares Outstanding | 92.43M | 91.1M | 84.25M | 85.59M | 86.42M | 82.95M | 84.02M | 83.33M | 85.27M | 83.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MD Balance Sheet
Pediatrix Medical Group, Inc. (MD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 627.24M | 657.41M | 731.51M | 1.55B | 840.56M | 427.99M | 483.45M | 639.61M | 763.51M | 553.77M |
| Cash & Short-Term Investments | 70.49M | 58.67M | 182.38M | 1.23B | 487.11M | 103.06M | 177.74M | 348.51M | 499.72M | 328.97M |
| Cash Only | 60.2M | 36.74M | 107.87M | 1.12B | 387.39M | 9.82M | 73.26M | 229.94M | 375.24M | 205.78M |
| Short-Term Investments | 10.29M | 21.92M | 74.51M | 104.87M | 99.72M | 93.24M | 104.48M | 118.57M | 124.48M | 123.19M |
| Accounts Receivable | 504M | 506.72M | 434.27M | 241.93M | 316.02M | 296.79M | 279.88M | 272.6M | 242.31M | 224.8M |
| Days Sales Outstanding | 53.19 | 50.71 | 89.06 | 50.93 | 60.35 | 54.93 | 51.22 | 49.43 | 46.21 | 44.63 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 37.16M | 88.72M | 97.75M | 61.81M | 18.9M | 13.26M | 12.31M | 5.09M | 8.88M | 0 |
| Total Non-Current Assets | 5.24B | 5.28B | 3.41B | 1.8B | 1.88B | 1.92B | 1.74B | 1.51B | 1.48B | 1.52B |
| Property, Plant & Equipment | 123.54M | 133.04M | 129.09M | 132.16M | 135.62M | 140.21M | 145.93M | 78.44M | 73.51M | 1.51B |
| Fixed Asset Turnover | 27.99x | 27.41x | 13.79x | 13.12x | 14.09x | 14.06x | 13.67x | 25.66x | 26.04x | 4.46x |
| Goodwill | 4.6B | 4.69B | 1.48B | 1.48B | 1.51B | 1.53B | 1.38B | 1.24B | 1.26B | 1.27B |
| Intangible Assets | 639.93M | 588.31M | 28.59M | 26.64M | 21.57M | 18.49M | 21.24M | 11.6M | 16.86M | 15.94M |
| Long-Term Investments | 80.68M | 69.7M | 0 | 0 | 0 | 0 | 0 | 0 | 20.8M | 20.8M |
| Other Non-Current Assets | -352.01M | -333.98M | 1.69B | 107.36M | 131.03M | 123.18M | 82.17M | 76.6M | 37.36M | 245.79M |
| Total Assets | 5.87B▲ 0% | 5.93B▲ 1.2% | 4.15B▼ 30.1% | 3.35B▼ 19.2% | 2.72B▼ 18.7% | 2.35B▼ 13.8% | 2.22B▼ 5.5% | 2.15B▼ 3.0% | 2.25B▲ 4.4% | 2.07B▲ 0% |
| Asset Turnover | 0.59x | 0.61x | 0.43x | 0.52x | 0.70x | 0.84x | 0.90x | 0.94x | 0.85x | 0.90x |
| Asset Growth % | 9.89% | 1.15% | -30.14% | -19.25% | -18.68% | -13.76% | -5.46% | -3.02% | 4.37% | 19.47% |
| Total Current Liabilities | 438.02M | 469.34M | 541.82M | 444.33M | 427.37M | 426.98M | 388.95M | 434.11M | 458.91M | 442.64M |
| Accounts Payable | 34.63M | 31.06M | 35.41M | 59.77M | 36.65M | 31.86M | 34.59M | 46.43M | 37.22M | 0 |
| Days Payables Outstanding | 5.14 | 4.27 | 10.12 | 16.98 | 9.57 | 7.73 | 8.03 | 10.87 | 9.42 | 10.06 |
| Short-Term Debt | 1.4M | 253K | 0 | 0 | 0 | 12.5M | 12.5M | 18.75M | 38.4M | 204.31M |
| Deferred Revenue (Current) | -496.79M | -469.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 192.89M | 149.89M | 106.89M | 0 | 0 | 0 | 0 | 0 | 94.63M | 238.33M |
| Current Ratio | 1.43x | 1.40x | 1.35x | 3.49x | 1.97x | 1.00x | 1.24x | 1.47x | 1.66x | 1.66x |
| Quick Ratio | 1.43x | 1.40x | 1.35x | 3.49x | 1.97x | 1.00x | 1.24x | 1.47x | 1.66x | 1.66x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 34.58 |
| Total Non-Current Liabilities | 2.36B | 2.38B | 2.11B | 2.16B | 1.4B | 1.03B | 981.8M | 953.65M | 921.93M | 749.08M |
| Long-Term Debt | 1.85B | 1.97B | 1.73B | 1.73B | 1B | 627.65M | 611.59M | 593.57M | 594.64M | 425.41M |
| Capital Lease Obligations | 0 | 188K | 44.64M | 49.87M | 41.4M | 52.94M | 54.07M | 35.49M | 27.27M | 84.76M |
| Deferred Tax Liabilities | 147.8M | 131.24M | 56.47M | 61.75M | 41.41M | 33.64M | 34.31M | 34.25M | 57.02M | 150.04M |
| Other Non-Current Liabilities | 418.4M | 372.55M | 273.74M | 310.62M | 313.43M | 315.04M | 281.84M | 290.34M | 243M | 1.1B |
| Total Liabilities | 2.8B | 2.85B | 2.65B | 2.6B | 1.83B | 1.46B | 1.37B | 1.39B | 1.38B | 1.19B |
| Total Debt | 1.85B | 1.97B | 1.79B | 1.8B | 1.07B | 717.08M | 701.65M | 662.31M | 660.3M | 629.72M |
| Net Debt | 1.79B | 1.94B | 1.69B | 680.84M | 678.44M | 707.26M | 628.39M | 432.37M | 285.06M | 423.94M |
| Debt / Equity | 0.60x | 0.64x | 1.20x | 2.41x | 1.19x | 0.80x | 0.83x | 0.87x | 0.76x | 0.76x |
| Debt / EBITDA | 3.18x | 3.73x | 9.07x | 14.26x | 4.53x | 3.44x | 16.13x | - | 2.61x | 2.55x |
| Net Debt / EBITDA | 3.08x | 3.66x | 8.52x | 5.38x | 2.89x | 3.39x | 14.45x | - | 1.13x | 1.13x |
| Interest Coverage | 6.17x | 4.78x | 1.49x | 1.06x | 2.97x | 3.05x | -0.15x | -1.49x | 7.02x | 16.53x |
| Total Equity | 3.07B▲ 0% | 3.09B▲ 0.7% | 1.5B▼ 51.5% | 747.72M▼ 50.1% | 896.69M▲ 19.9% | 891.63M▼ 0.6% | 849.06M▼ 4.8% | 764.94M▼ 9.9% | 865.85M▲ 13.2% | 878.58M▲ 0% |
| Equity Growth % | 11.07% | 0.7% | -51.46% | -50.12% | 19.92% | -0.56% | -4.77% | -9.91% | 13.19% | 64.13% |
| Book Value per Share | 32.72 | 33.71 | 17.79 | 8.74 | 10.38 | 10.60 | 10.33 | 9.18 | 10.15 | 10.58 |
| Total Shareholders' Equity | 3.07B | 3.09B | 1.5B | 747.49M | 896.49M | 891.63M | 849.06M | 764.94M | 865.85M | 878.58M |
| Common Stock | 937K | 878K | 842K | 856K | 864K | 829K | 840K | 859K | 830K | 821K |
| Retained Earnings | 2.05B | 2.09B | 510.13M | -286.35M | -155.39M | -89.06M | -149.47M | -248.54M | -83.15M | -53.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -169.62M | -207.82M | 78K | 3.53M | 1.32M | -3.73M | -2.21M | -1.07M | 610K | 77K |
| Minority Interest | 0 | 0 | 0 | 232K | 205K | 0 | 0 | 0 | 0 | 0 |
MD Cash Flow Statement
Pediatrix Medical Group, Inc. (MD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 511.38M | 289.93M | 357.71M | 204.62M | 76.74M | 166.94M | 137.32M | 206.57M | 271.09M | 271.09M |
| Operating CF Margin % | 14.79% | 7.95% | 20.1% | 11.8% | 4.02% | 8.47% | 6.88% | 10.26% | 14.16% | - |
| Operating CF Growth % | 15.23% | -43.31% | 23.38% | -42.8% | -62.5% | 117.55% | -17.74% | 50.43% | 31.23% | 53.27% |
| Net Income | 320.37M | 268.63M | 42.21M | -9.58M | 108.01M | 62.57M | -60.41M | -99.07M | 0 | 174.22M |
| Depreciation & Amortization | 102.88M | 111.28M | 25.93M | 28.44M | 32.15M | 35.64M | 36.17M | 33.18M | 0 | 22.72M |
| Stock-Based Compensation | 29.57M | 38.7M | 33.41M | 39.04M | 18.97M | 16.13M | 12.32M | 11.87M | 0 | 11.97M |
| Deferred Taxes | -60.07M | -24.15M | -55.72M | 36.29M | -31.24M | -22.77M | 3.24M | -2.13M | 0 | 44.99M |
| Other Non-Cash Items | 981K | -7.42M | 295.85M | 57.7M | -27.8M | 43.55M | 157.63M | 174.49M | 229.26M | -130.64M |
| Working Capital Changes | 117.65M | -97.11M | 16.03M | 52.73M | -23.36M | 31.83M | -11.63M | 88.24M | 41.83M | 135.78M |
| Change in Receivables | 7.8M | -36.6M | -17.61M | 31.01M | -72.73M | -5.54M | 26.28M | 10.29M | 30.56M | 17.96M |
| Change in Inventory | 70.26M | -66.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 24.55M | 15.39M | 46.2M | 47.91M | 21.33M | 420K | 0 | 51.14M | 28.33M | -44.57M |
| Cash from Investing | -576.61M | -142.77M | 102.45M | 815.51M | -53.07M | -56.95M | -48.18M | -35.41M | -18.3M | -22.81M |
| Capital Expenditures | -49.31M | -48.87M | -19.27M | -28.79M | -32.25M | -29.71M | -33.33M | -22.02M | 0 | -21.39M |
| CapEx % of Revenue | 1.43% | 1.34% | 1.08% | 1.66% | 1.69% | 1.51% | 1.67% | 1.09% | 0.96% | - |
| Acquisitions | -531.7M | -91.73M | -46.98M | -2.23M | -5.2M | -28.17M | -6.67M | -8.17M | 0 | -30.2M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 6.71M | -18.39M | 152.69M | 874.94M | 2.93M | 1.38M | 807K | 6.83M | -18.3M | 61.84M |
| Cash from Financing | 89.74M | -170.61M | -393.07M | -4.16M | -760.12M | -487.55M | -25.71M | -14.48M | -107.49M | -129.09M |
| Debt Issued (Net) | 145.34M | 129M | -239.5M | -1.16M | -762.66M | -405.17M | -19.12M | -15.39M | -20.75M | -15.72M |
| Equity Issued (Net) | -70.19M | -302.16M | -134.02M | -1.48M | 2.13M | -83.11M | 3.99M | 1.94M | -83.5M | -83.29M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -70.19M | -302.16M | -145.28M | -8.49M | -4.72M | -88.51M | -919K | -1.7M | -86.68M | -106.56M |
| Other Financing | 14.59M | 2.55M | -19.55M | -1.51M | 407K | 732K | -10.59M | -1.03M | -3.25M | -30.08M |
| Net Change in Cash | 24.5M▲ 0% | -23.45M▼ 195.7% | 67.1M▲ 386.1% | 1.02B▲ 1414.2% | -736.45M▼ 172.5% | -377.57M▲ 48.7% | 63.43M▲ 116.8% | 156.68M▲ 147.0% | 145.3M▼ 7.3% | 106.8M▲ 0% |
| Free Cash Flow | 462.07M▲ 0% | 241.06M▼ 47.8% | 338.44M▲ 40.4% | 175.83M▼ 48.0% | 44.49M▼ 74.7% | 137.23M▲ 208.5% | 104M▼ 24.2% | 184.55M▲ 77.5% | 252.63M▲ 36.9% | 237.66M▲ 0% |
| FCF Margin % | 13.36% | 6.61% | 19.02% | 10.14% | 2.33% | 6.96% | 5.21% | 9.17% | 13.2% | 12.3% |
| FCF Growth % | 14.23% | -47.83% | 40.4% | -48.05% | -74.7% | 208.47% | -24.22% | 77.46% | 36.89% | 22.3% |
| FCF per Share | 4.93 | 2.63 | 4.02 | 2.05 | 0.51 | 1.63 | 1.27 | 2.21 | 2.96 | 2.96 |
| FCF Conversion (FCF/Net Income) | 1.60x | 1.08x | -0.24x | -0.26x | 0.59x | 2.52x | -2.27x | -2.09x | 1.64x | 1.36x |
| Interest Paid | 73.84M | 82.54M | 95.44M | 110.49M | 86.54M | 116.23M | 42.28M | 40M | 0 | 0 |
| Taxes Paid | 75.43M | 185.42M | 86.27M | 0 | 54.73M | 26.91M | 30.84M | 4.67M | 0 | 0 |
MD Key Ratios
Pediatrix Medical Group, Inc. (MD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 11% | 8.73% | -65.3% | -70.9% | 15.93% | 7.42% | -6.94% | -12.28% | 20.28% | 20.09% |
| Return on Invested Capital (ROIC) | 7.77% | 6.77% | 3.14% | 3.19% | 10.13% | 8.16% | 0.36% | -3.85% | 14.76% | 14.76% |
| Gross Margin | 28.92% | 27.13% | 28.27% | 25.91% | 26.85% | 23.68% | 21.13% | 22.57% | 24.66% | 19.95% |
| Net Margin | 9.26% | 7.37% | -84.15% | -45.93% | 6.85% | 3.36% | -3.03% | -4.92% | 8.64% | 9.02% |
| Debt / Equity | 0.60x | 0.64x | 1.20x | 2.41x | 1.19x | 0.80x | 0.83x | 0.87x | 0.76x | 0.76x |
| Interest Coverage | 6.17x | 4.78x | 1.49x | 1.06x | 2.97x | 3.05x | -0.15x | -1.49x | 7.02x | 16.53x |
| FCF Conversion | 1.60x | 1.08x | -0.24x | -0.26x | 0.59x | 2.52x | -2.27x | -2.09x | 1.64x | 1.36x |
| Revenue Growth | 8.64% | 5.46% | -51.2% | -2.57% | 10.22% | 3.18% | 1.15% | 0.92% | -4.92% | -2.25% |
MD SEC Filings & Documents
Pediatrix Medical Group, Inc. (MD) SEC filings — annual & quarterly reports (10-K, 10-Q)
MD Frequently Asked Questions
Pediatrix Medical Group, Inc. (MD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pediatrix Medical Group, Inc. (MD) reported $1.93B in revenue for fiscal year 2025. This represents a 2291% increase from $80.8M in 1996.
Pediatrix Medical Group, Inc. (MD) saw revenue decline by 4.9% over the past year.
Yes, Pediatrix Medical Group, Inc. (MD) is profitable, generating $174.2M in net income for fiscal year 2025 (8.6% net margin).
Dividend & Returns
Pediatrix Medical Group, Inc. (MD) has a return on equity (ROE) of 20.3%. This is excellent, indicating efficient use of shareholder capital.
Pediatrix Medical Group, Inc. (MD) generated $237.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More MD
Pediatrix Medical Group, Inc. (MD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates